Astellas Pharma patented novel carbocyclic prolinamide derivatives for treating age-related macular degeneration and related eye diseases. The compounds are HTRA1 inhibitors, useful in prevention and treatment of various eye conditions. GlobalData’s report on Astellas Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Astellas Pharma, Cancer treatment biomarkers was a key innovation area identified from patents. Astellas Pharma's grant share as of January 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11866422B2) discloses a compound of Formula I as claimed. The compound described in the patent is likely to have specific structural characteristics and properties that make it unique and potentially valuable in various applications. The formula provided in the claim suggests a specific chemical structure that may have been determined to possess certain desirable traits or functions.
The patent claim for the compound of Formula I indicates that the inventors have identified a novel chemical entity with potential utility in different fields such as pharmaceuticals, materials science, or other industries. The specific details of the compound's structure and any associated benefits or advantages are likely to be further elaborated in the patent description. This patent grant signifies the recognition of the compound's novelty and inventiveness, providing the inventors with exclusive rights to its use and commercialization for a specified period. Further research and development based on this patented compound could lead to innovative products or technologies with practical applications in various sectors.
To know more about GlobalData’s detailed insights on Astellas Pharma, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
